UNSPSC 51412101: Bendazol

This classification denotes a vasodilating agent with the molecular formula C14H12N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26601THN1D, chemically known as 1h-benzimidazole, 2-(phenylmethyl)- (9ci) but generally known as bendazol, which bears US NIH Compound Identifier 12132. Bendazol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bendazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05709MIG.

UNSPSC 51412101 Bendazol is a Commodity code covering pharmaceutical active ingredients and formulations for emergency medical and clinical use. State and local governments procure bendazol and related advanced life support medications through fire rescue departments, public health agencies, and cooperative purchasing alliances to supply paramedics, emergency responders, and hospital systems. The solicitations show two distinct procurement patterns: direct acquisition of finished emergency medications (such as Labetalol, Epinephrine, Adenosine, and Diltiazem formulations) by municipal fire departments, and bulk generic pharmaceutical supply agreements through multistate cooperative vehicles serving multiple state and local health agencies. Issuing bodies include city purchasing departments acting for fire rescue services, state health agencies, and cooperative purchasing organizations spanning multiple states. Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the range of buyers using this code.

Recent activity concentrates in Florida, Texas, and the upper Midwest. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, soliciting sealed bids for advanced life support medications (Labetalol, Epinephrine, Adenosine, Diltiazem) with an estimated value of $40,000 and a response deadline of April 8, 2026; the contract includes a 5 percent Small Local Business Enterprise discount and requires nine-month minimum expiration dates and ten-day delivery. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, gathering vendor capability information on direct-to-manufacturer prescription programs to inform future formal procurement strategy. MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products serving state and local facilities across Minnesota and Oregon, with proposals due March 26, 2026; vendors must contract through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, or Morris & Dickson Co., LLC, and evaluation weighs price competitiveness at 75 percent. All three solicitations require FDA compliance, Safety Data Sheets or Good Manufacturing Practices certification, and compliance with federal drug supply chain security standards.